Registrational trial of IMO-2125 in PD1 refractory metastatic melanoma.
Phase of Trial: Phase III
Latest Information Update: 10 Sep 2017
At a glance
- Drugs IMO 2125 (Primary) ; Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Idera Pharmaceuticals
- 10 Sep 2017 This trial is expected to begin in this first quarter of 2018, according to an Idera Pharmaceuticals media release.
- 21 Mar 2017 New trial record
- 15 Mar 2017 According to an Idera Pharmaceuticals media release, comany expects to conduct a meeting with the US FDA to discuss the plans for this trial in first quarter of 2017.